You just read:

Praxbind™ (idarucizumab), A Specific Antidote for Immediate Reversal of Pradaxa® (dabigatran etexilate)[1] Now Approved in Canada With Conditions

News provided by

Boehringer Ingelheim (Canada) Ltd.

May 16, 2016, 08:00 ET